Belite Bio BLTE
NASDAQ BLTE
$193.81 +22.72 (+13.28%)
As of: Sep 4, 2026 · 3:59 PM EDT

Belite Bio (BLTE) Total Debt (2021)

Belite Bio (BLTE) posted quarterly Total Debt of $71000.0 for Q4 2021.

Analysis

Belite Bio (BLTE) Total Debt (2021) Analysis & Trends

Belite Bio's Total Debt history runs 1 years deep, the most recent figure standing at $71000.0 for Q4 2021.

  • In Q4 2021, Total Debt changed N/A year-over-year to $71000.0; the TTM figure through Dec 2021 stood at $71000.0 (changed N/A YoY), while the FY2021 annual figure was $71000.0, changed N/A from the prior year.
  • Total Debt for Q4 2021 stood at $71000.0.
  • The five-year high for Total Debt was $71000.0 in Q4 2021, with the low at $71000.0 in Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.07 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.34 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 546.77 Mn
10 Belite Bio 6.44 Bn 6.44 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 71,000.00